1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

AstraZeneca/Daiichi Sankyo Line Up More Enhertu Indications

Promising Phase II Data In Multiple Tumor Types

 
• By Kevin Grogan

The high-profile antibody-drug conjugate has shown its potential to improve outcomes for heavily pre-treated patients in diseases such as bladder, cervical, pancreatic and rare cancers in a mid-stage trial. 

Dart
Enhertu on target for more indications • Source: Shutterstock

AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s Enhertu is on the rise following a string of regulatory approvals for breast, lung and gastric cancers but new data suggests that the antibody-drug conjugate (ADC) could be an effective treatment for a wide range of other HER2-expressing tumors.

The UK major says that high-level results of a mid-stage trial of Enhertu (trastuzumab deruxtecan) met the prespecified target for objective response rate (ORR) and durable response across multiple HER2-expressing advanced solid tumours in heavily pre-treated patients

More from Anticancer

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapy Areas

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.